Alnylam Pharmaceuticals Inc 2025年季度报告

Washington, D.C.20549____________________________________________ FORM10-Q____________________________________________ ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period endedMarch31, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number001-36407__________________________________________ ALNYLAM PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter)__________________________________________ Delaware(State or Other Jurisdiction ofIncorporation or Organization) 675 West Kendall Street,Henri A. Termeer SquareCambridge,MA(Address of Principal Executive Offices) 02142(Zip Code) (617)551-8200(Registrant’s Telephone Number, Including Area Code)__________________________________________ Securities registered pursuant to Section12(b) of the Act: Name of Each Exchange on WhichRegistered The Nasdaq Stock Market LLC Common Stock, $0.01par value pershare Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.Yes x No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yesx No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule12b-2 of the Exchange Act. Large accelerated filerxNon-accelerated filer☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No x ALNYLAM PHARMACEUTICALS, INC.QUARTERLY REPORT ON FORM10-Q TABLE OF CONTENTS PART I.FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS (Unaudited)CONDENSED CONSOLIDATED BALANCE SHEETS AS OFMARCH31, 2025AND DECEMBER 31, 20245CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVELOSSFORTHETHREEMONTHS ENDEDMARCH 31, 2025AND 20246CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) FOR THE THREEMONTHS ENDEDMARCH 31, 2025AND 20247CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THETHREEMONTHS ENDEDMARCH31, 2025AND 20248NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS9ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFOPERATIONS24ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK35ITEM 4. CONTROLS AND PROCEDURES35PART II.OTHER INFORMATIONITEM 1.LEGAL PROCEEDINGS36ITEM 1A.RISK FACTORS36ITEM 5. OTHER INFORMATION72ITEM 6. EXHIBITS72SIGNATURES73 “Alnylam,” AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO are registered trademarks of Alnylam Pharmaceuticals, Inc. Ourlogo, trademarks and service marks are property of Alnylam. All other trademarks or service marks appearing in this Quarterly Report onForm 10-Q are the property of their respective holders.®®®® CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend these forward-looking statements to becovered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 andare including this statement for purposes of complying with those safe harbor provisions. All statements other than statements of historicalfact contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-lookingstatements by terminology such as “may,” “will,” “should,” “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,”“predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology. These forward-looking statementsinclude, but are not limited to, statements about: •our views with respect to the potential for our approved and investigational RNAi therapeutics and those of our collaborators,including AMVUTTRA, ONPATTRO, GIVLAARI, OXL